About SynCardia
SynCardia is a company based in Tucson (United States) founded in 2001 was acquired by Picardmedia.de in September 2021. SynCardia has raised $60.96 million across 11 funding rounds from investors including Delta Electronics, SWK Holdings and Athyrium Capital Management. SynCardia offers products and services including SynCardia Total Artificial Heart and Emperor Total Artificial Heart. SynCardia operates in a competitive market with competitors including CVRx, Sequana Medical, Adona Medical, Element Science and V-Wave, among others.
- Headquarter Tucson, United States
- Stage Public
- SectorsHealthcare
- Website syncardia.com
- Social LinkedIn X Facebook YouTube
- Acquired by Picardmedia.de (Sep 2021)
- Legal Name Picard Medical, Inc.
- Annual Revenue$4.94 M (USD)12.5as on Dec 31, 2025
- Net Profit-$27 M (USD)-28.25as on Dec 31, 2025
- EBITDA-$12.74 M (USD)3.21as on Dec 31, 2025
- Total Equity Funding$60.96M (USD)
in 11 rounds
- InvestorsDelta Electronics
& 5 more
- Acquired by
Products & Services of SynCardia
SynCardia offers a comprehensive portfolio of products and services, including SynCardia Total Artificial Heart and Emperor Total Artificial Heart.
Temporary replacement for failing hearts in transplant-eligible patients.
Next-generation implantable heart for end-stage cardiac failure support.
Apps and channels of SynCardia
its YouTube channel SynCardia Systems, LLC has 53 subscribers and 24 videos.
Videos from SynCardia
The most watched videos on SynCardia's YouTube channel, SynCardia Systems, LLC (53 subscribers). Click a video to play it here.
More on SynCardia Systems, LLC.
Funding Insights of SynCardia
SynCardia has successfully raised a total of $60.96M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $60.96M
- Total Rounds 11
- First Round $2.62M
(May 2003)
- Investors Count 4
Latest 10 of 11 funding rounds of SynCardia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2015 | – | Series E | – | Delta Electronics | – |
| Oct 2014 | $6.42M | Series E | – | – | – |
| Dec 2013 | $14M | Series E | – | SWK Holdings, Athyrium Capital Management | – |
| Mar 2013 | $4M | Series D | – | – | – |
| Mar 2013 | $15M | Debt – Conventional | – | – | |
| Mar 2011 | $4.99M | Series D | – | – | – |
| Nov 2010 | $3.6M | Series D | – | – | – |
| Jun 2009 | $10.3M | Series D | – | – | |
| Jan 2006 | $11.33M | Series C | – | – | – |
| May 2004 | $3.7M | Series B | – | – | – |
6 investors in total: 6 institutional.
Investors in SynCardia
SynCardia has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Delta Electronics, SWK Holdings and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | – | athyrium.com | New York, United States | |
Tech focused early stage VC firm investing in the US | – | highway12ventures.com | Boise, United States | |
Versa Capital is focused on private equity investments for business transformation. | – | versa.com | Philadelphia, United States | |
Power management and thermal solutions are provided globally. | 1971 | deltaww.com | Taipei, Taiwan | |
Investments and advisory services are provided by the holding company. | 2009 | swkhold.com | Dallas, United States | |
- | – | picardmedia.de | - |
Investor details for SynCardia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of SynCardia
SynCardia is a publicly listed company on the AMEX with ticker symbol PMI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Aug 2025
- Listed onNYSEMKT: PMI
- Listed entityPicard Medical, Inc.
- Exchange sectorHealth technology
- ISINUS71953R2076
- Share price$9.48 (-2.07% on the day) · 2026-10-09
- Market capitalisation$22.2M
- EPS (diluted, trailing year)$-20.65
- Volume (last session)300,937
Financials of SynCardia
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $4.9M | -$27.0M | -$12.7M |
| 2024 | $4.4M | -$21.1M | -$13.2M |
| 2023 | $5.0M | -$15.6M | -$14.9M |
| 2022 | $4.1M | -$11.2M | -$10.5M |
Detailed financial statements for SynCardia
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of SynCardia
6 dated milestones of SynCardia across 24 years, from founding to its latest funding, stage changes and deals.
- Founded SynCardia is founded.
- Funding First funding round of $2.6M.
- Funding Latest funding round, Series E,.
- Exit Acquired by Versa Capital.
- Exit Acquired by Picardmedia.de.
- IPO Lists on the stock exchange (IPO).
Competitors of SynCardia
SynCardia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CVRx, Sequana Medical, Adona Medical, Element Science and V-Wave, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cvrx.com | 2001 | Minneapolis, United States | $368.5M | 142 | Implantable technology for hypertension and heart failure is developed. | |
| sequanamedical.com | 2006 | Zurich, Switzerland | $35.5M | – | Implantable battery-powered pumps for ascites removal are developed. | |
| adonamed.com | 2017 | Campbell, United States | $71M | – | Medical devices for heart failure management are developed. | |
| elementscience.com | 2013 | San Francisco, United States | $192.6M | – | Wearable patch defibrillators are developed for sudden cardiac arrest treatment. | |
| vwavemedical.com | 2009 | Caesarea, Israel | $128M | – | Implantable inter-atrial shunts are developed to treat chronic heart failure. | |
| ancoraheart.com | 2001 | San Francisco, United States | $151.26M | 89 | Minimally invasive ventriculoplasty system for heart failure and FMR | |
| bioventrix.com | 2003 | San Ramon, United States | $181.42M | 20 | Ventricular reconstruction devices for heart failure are developed. | |
| heartware.com | 2005 | Framingham, United States | $12.38M | 547 | Miniaturized ventricular assist devices are developed for heart failure treatment. | |
| reprievecardio.com | 2018 | Milford, United States | $119.37M | – | Medical device for acute heart failure treatment is developed. |
Detailed competitors of SynCardia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SynCardia
The website of SynCardia (syncardia.com) receives about 3.8K visits a month.
- Monthly visits3.8K
▼ 11.9% vs previous month
Websites whose visitors overlap most with SynCardia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
emedicine.medscape.com | emedicine.medscape.com | 100% | – | – | – |
transplants.ucla.edu | transplants.ucla.edu | 97% | – | – | – |
| thoratec.com | 92% | – | – | View details | |
| fda.gov | 86% | – | #7,606 | View details | |
asts.org | asts.org | 78% | – | #1,211,314 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for SynCardia
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Syncardia
Complete news archive for SynCardia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SynCardia
10 companies that operate in the same segment as SynCardia (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | USD 57.22 M | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SynCardia
SynCardia was founded in 2001 and raised its 1st funding round 2 years after it was founded.
SynCardia is headquartered in Tucson, United States. It is registered at Tucson, Arizona, United States.
SynCardia is a funded company, having raised a total of $60.96M across 11 funding rounds to date. The company's 1st funding round was a Series B of $3.7M, raised on May 2003.
Annual revenue of SynCardia is $4.94M as on Dec 31, 2025.
SynCardia Systems has developed a temporary total artificial heart in two sizes - 70cc and 50cc. The 70cc product is FDA approved both as a destination therapy and a bridge to transplant. SynCardia also provides a portable driver, which powers the SynCardia Heart while allowing clinically stable patients to be discharged from the hospital to live at home. It claims to have over 1,400 implants accounting for more than 400 patient years. The company filed for an IPO in Aug 2015 and withdrew its application two months later.
SynCardia's top competitors include Sequana Medical, CVRx and Adona Medical.
SynCardia offers SynCardia Total Artificial Heart and Emperor Total Artificial Heart.
Yes, SynCardia is publicly traded on AMEX under the ticker symbol PMI.
SynCardia has 6 investors. Key investors include Delta Electronics, SWK Holdings, Athyrium Capital Management, Highway 12 Ventures, and Picardmedia.de.
SynCardia operates through Syncardia Systems, Llc.
Yes. SynCardia was acquired by Picardmedia.de in September 2021.